Trial Updates

Clinical trials of BTK inhibitors in MS 1:06
Clinical trials of BTK inhibitors in MS
Celia Oreja-Guevara • 24 Feb 2022
Update: novel disease-modifying treatments in development for Huntington’s disease 2:20
Update: novel disease-modifying treatments in development for Huntington’s disease
Anne Rosser • 23 Sep 2021
REPAIR-MS and REPAIR-PD: tackling disease progression with gold nanocrystals 8:23
REPAIR-MS and REPAIR-PD: tackling disease progression with gold nanocrystals
Robert Glanzman • 13 Oct 2021
Updates on RADIUS-R & RADIUS-P: elezanumab for patients with relapsing and progressive forms of MS 4:34
Updates on RADIUS-R & RADIUS-P: elezanumab for patients with relapsing and progressive forms of MS
Bruce Cree • 21 Oct 2021
Phase II and III studies of CNM-Au8 in ALS 1:32
Phase II and III studies of CNM-Au8 in ALS
Robert Glanzman • 13 Oct 2021
Using virtual placebo to assess long-term effect of siponimod on disability progression in SPMS 3:57
Using virtual placebo to assess long-term effect of siponimod on disability progression in SPMS
Bruce Cree • 21 Oct 2021
Updates on N-MOmentum: inebilizumab versus placebo in patients with NMOSD 2:44
Updates on N-MOmentum: inebilizumab versus placebo in patients with NMOSD
Bruce Cree • 21 Oct 2021
PREVENT study: eculizumab in AQP4-IgG-positive NMOSD 5:10
PREVENT study: eculizumab in AQP4-IgG-positive NMOSD
Kazuo Fujihara • 4 Oct 2021
Symptomatic treatment of NMOSD 2:24
Symptomatic treatment of NMOSD
Kazuo Fujihara • 4 Oct 2021
Updates on SWIFT DIRECT: bridging thrombolysis vs direct mechanical thrombectomy 3:08
Updates on SWIFT DIRECT: bridging thrombolysis vs direct mechanical thrombectomy
Jan Gralla • 4 Oct 2021
PD_PAL: developing new standards of palliative care in Parkinson’s disease 1:26
PD_PAL: developing new standards of palliative care in Parkinson’s disease
Victor McConvey • 13 Sep 2021
Diagnostic criteria and treatment updates for NMOSD 5:44
Diagnostic criteria and treatment updates for NMOSD
Kazuo Fujihara • 4 Oct 2021
VISIONARY-MS update: bioenergetic nanocatalysts under investigation as a novel DMT in RRMS 2:15
VISIONARY-MS update: bioenergetic nanocatalysts under investigation as a novel DMT in RRMS
Robert Glanzman • 13 Oct 2021
Phase III SPARX3 trial of moderate- vs. high-intensity exercise to slow progression in PD 4:37
Phase III SPARX3 trial of moderate- vs. high-intensity exercise to slow progression in PD
Daniel Corcos • 23 Sep 2021
The impact of LCIG on dyskinesia duration & severity in PD 4:19
The impact of LCIG on dyskinesia duration & severity in PD
Alfonso Fasano • 22 Sep 2021
Phase III ULTIMATE I & II update: ublituximab versus teriflunomide in relapsing MS 3:26
Phase III ULTIMATE I & II update: ublituximab versus teriflunomide in relapsing MS
Lawrence Steinman • 15 Oct 2021
The content of VJNeurology is intended for healthcare professionals